U.S. markets open in 5 hours 45 minutes

T2 Biosystems, Inc. (TTOO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6900-0.0200 (-1.17%)
At close: 03:59PM EST
1.6800 -0.01 (-0.59%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.7100
Bid0.0000 x 1100
Ask0.0000 x 3000
Day's Range1.6700 - 1.7400
52 Week Range1.5550 - 30.5000
Avg. Volume368,274
Market Cap12.369M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.3350
Earnings DateFeb 15, 2023 - Feb 20, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.35
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TTOO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • T2 Biosystems, Inc.
    Analyst Report: Danaher CorporationIn 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2022, the company announced plans to divest its environmental and applied solutions group in 2023, which would leave it focused entirely on life sciences and diagnostics.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Simply Wall St.

    T2 Biosystems Third Quarter 2022 Earnings: Misses Expectations

    T2 Biosystems ( NASDAQ:TTOO ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.68m (down 51% from 3Q...

  • GlobeNewswire

    T2 Biosystems Announces Third Quarter 2022 Financial Results

    Achieves record quarterly sepsis and related revenue and advances product pipelineLEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the third quarter ended September 30, 2022. Recent Commercial and Financial Highlights Achieved third quarter total revenue of $3.7 million, including product revenue of $2.6 million.A

  • GlobeNewswire

    T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement

    LEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”). The amendment extends both the interest-only period and the maturity date by one year from December 30, 2023 to December 30, 2024. No other material amendments were made to the Term Loan Agreement. “We conti